CompletedPHASE2, PHASE3NCT05506943
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Studying Carcinoma of the ampulla of Vater
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Compass Therapeutics
- Principal Investigator
- Minori Rosales, MD, PHDCompass Therapeutics
- Intervention
- CTX-009(drug)
- Enrollment
- 168 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (30)
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- University of Arizona, Tucson, Arizona, United States
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Stanford Medicine Cancer Center, Palo Alto, California, United States
- University of California San Francisco, San Francisco, California, United States
- Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- AdventHealth Orlando, Orlando, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05506943 on ClinicalTrials.govOther trials for Carcinoma of the ampulla of Vater
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07282912Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) LevelsYale University
- RECRUITINGPHASE3NCT07081360Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary CancerMinia University
- RECRUITINGNANCT06801899ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary CancerInsel Gruppe AG, University Hospital Bern
- RECRUITINGNANCT05780684Individualized Dose Escalation of 5-FU for Gastrointestinal CancerDartmouth-Hitchcock Medical Center
- ENROLLING BY INVITATIONNANCT06076252Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary CarcinomaAffiliated Hospital of Guangdong Medical University
- RECRUITINGNANCT06068023The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.Fondazione Poliambulanza Istituto Ospedaliero
- RECRUITINGNANCT05497531Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic CancersUniversity of California, Irvine
- RECRUITINGPHASE1, PHASE2NCT05116072Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative FistulaUniversity Hospital, Lille